Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A...

Area of Science:

• Oncology
• Gastroenterology
• Clinical Pharmacology

Background:

• Advanced gastrointestinal neuroendocrine tumors (GI NETs) represent a heterogeneous group of malignancies.
• Treatment strategies for advanced GI NETs have evolved, necessitating an understanding of current patterns of care.
• Tertiary referral centers manage a significant proportion of patients with complex GI NET cases.

Purpose of the Study:

• To evaluate treatment patterns and patient outcomes in advanced GI NETs.
• To analyze the utilization of somatostatin analogs (SSAs), liver-directed therapy (LDT), and chemotherapy.
• To assess overall survival (OS) and time-to-progression in patients with advanced GI NETs.

Main Methods:

• Retrospective chart review of 273 patients with advanced GI NETs diagnosed between July 2011 and December 2014.
• Analysis of baseline characteristics, treatment sequences, and health care resource utilization.
• Kaplan-Meier analysis for time-to-event outcomes, including treatment discontinuation, progression, and OS.

Main Results:

• Somatostatin analogs (SSAs) were the predominant first-line therapy (89% alone, 2% in combination).
• Median time to first-line SSA discontinuation was 154.0 months; median OS was 151.8 months.
• Patients received multiple lines of therapy, with SSAs frequently used in subsequent treatment regimens.

Conclusions:

• Somatostatin analogs are a cornerstone in the management of advanced GI NETs, utilized extensively in first-line and later treatment settings.
• Patients with advanced GI NETs experience prolonged survival and often undergo multiple treatment modalities.
• Future research should investigate evolving treatment paradigms following recent therapeutic approvals for GI NETs.